- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium Inhalation Solution, Placebo
- Drug · Other
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 983 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Pismo Beach, California • San Diego, California + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 673
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dermatitis, Atopic
- Interventions
- Spesolimab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 4 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Afatinib, pembrolizumab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol
- Device · Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 15
- States / cities
- Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more
- Conditions
- Hypertension
- Interventions
- telmisartan 80 mg/hydrochlorothiazide 25 mg, valsartan 160 mg/hydrochlorothiazide 25 mg, placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 100
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 90 more
- Conditions
- Neoplasms
- Interventions
- BI 6727, IV infusion
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 19
- States / cities
- Beverly Hills, California • Los Angeles, California • Miami, Florida + 14 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- BIBF 1120
- Drug
- Lead sponsor
- AA Secord
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Charlottesville, Virginia • Norfolk, Virginia
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium, Placebo matching Olodaterol, Olodaterol
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 90
- States / cities
- Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 79 more
- Conditions
- HIV Infections
- Interventions
- Tipranavir, Ritonavir
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- Not listed
- Timeline
- Started 2004
- U.S. locations
- 115
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 74 more
- Conditions
- Alzheimer Disease
- Interventions
- BI 409306, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 7
- States / cities
- Orange, California • Sherman Oaks, California • West Palm Beach, Florida + 4 more
- Conditions
- Lung Cancer
- Interventions
- BIBW 2992
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer, Advanced Relapsed or Refractory Ovarian Cancer
- Interventions
- BI 3820768
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Houston, Texas
- Conditions
- Atrial Fibrillation, Device Related Thrombus, Left Atrial Appendage Thrombosis, Watchman LAA Closure Device
- Interventions
- Dabigatran Etexilate Oral Capsule
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Idiopathic Inflammatory Myopathies
- Interventions
- Placebo, Nerandomilast
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 18 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 456906, Placebo, Semaglutide
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 31
- States / cities
- Huntington Park, California • Los Angeles, California • Northridge, California + 27 more
- Conditions
- Heart Failure, Type II; Diabetes
- Interventions
- Empagliflozin, Placebo Oral Capsule
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Post-Traumatic Stress Disorder
- Interventions
- BI 1358894, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 37
- States / cities
- Little Rock, Arkansas • Glendale, California • Long Beach, California + 31 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- tiotropium bromide, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 50
- States / cities
- Montgomery, Alabama • Flagstaff, Arizona • Glendale, Arizona + 46 more
- Conditions
- Heart Failure
- Interventions
- SGLT2i, beta blocker, ARNI, MRA, MTD, Education-First
- Drug · Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 503 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, empagliflozin (low dose qd), Empagliflozin (high dose qd), empagliflozin (high dose bid), empagliflozin (low dose bid)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 983 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 39
- States / cities
- Florence, Alabama • Jonesboro, Arkansas • Lomita, California + 34 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Olodaterol (BI1744), placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 625 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 21
- States / cities
- Jasper, Alabama • Berkeley, California • Los Angeles, California + 17 more
- Conditions
- Urological Manifestations
- Interventions
- tamsulosin hydrochloride
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Hoover, Alabama + 35 more
- Conditions
- Thromboembolism
- Interventions
- dabigatran etexilate 150 mg, warfarin (INR 2-3)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 23
- States / cities
- Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 19 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- TARA v3.1, only non-pharmacological self-management support, TARA v3.2, both non-pharmacological and pharmacological self-management support
- Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Gastonia, North Carolina • Charleston, South Carolina